Market Overview:
The global small molecule inhibitors for cancer therapy market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The growth of this market can be attributed to the increasing incidence of cancer, rising demand for targeted therapies, and technological advancements in the field of small molecule inhibitors. Based on type, the global small molecule inhibitors for cancer therapy market is segmented into tyrosine kinase inhibitor, histone deacetylase inhibitor, and target of rapamycin inhibitor. The tyrosine kinase inhibitor segment is expected to account for the largest share of the global market in 2018 owing to its high efficacy and growing demand as a targeted therapy against various types of cancers. Based on application, the hospital segment is expected to account for the largest share of the global market in 2018 owing to rising demand for targeted therapies and increasing incidence ratesof various types if cancers across hospitals globally.
Product Definition:
Small molecule inhibitors are chemicals that can block the action of enzymes or proteins. They are used to treat cancer by stopping the growth of tumors.
Tyrosine Kinase Inhibitor:
Tyrosine kinase inhibitor (TKIs) are a type of drug that inhibits the activity of tyrosine kinase. Tyrosine kinases are enzymes involved in the cellular processes such as signal transduction, cell motility, and proliferation. The most commonly used TKIs currently available in the market are sunitinib malate, sutentib malutamide, and tofacitinib citrate.
Histone Deacetylase Inhibitor:
Histone deacetylase (HDAC) inhibitors are small molecule drugs that target the epigenetic silencing of tumor suppressor genes. They are used in cancer therapy to treat patients with advanced melanoma, lymphoma, and breast cancer as well as for the treatment of brain tumors.
Application Insights:
The other application segment dominated the global small molecule inhibitors for cancer therapy market in 2017, accounting for over 60% of the revenue share. This can be attributed to growing awareness about availability of affordable drugs that are less effective than conventional ones. The other applications include personal care products, cosmetics and agriculture products among others. Personal care product manufacturers often turn to these molecules as they offer a cost-effective alternative while trying to find an edge over their competitors by coming up with new and innovative formulations.
Rapamycin is used in clinics & hospitals as it has fewer side effects when compared with chemotherapy or radiotherapy drugs; hence this segment is expected to grow at a lucrative rate during the forecast period owing to increasing cases of cancer across the globe coupled with rising demand for palliative treatment options that do not involve harsh chemotherapy or radiation therapies.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, such as Pfizer Inc.; Merck & Co., Inc.; and Celgene Corporation; coupled with high R&D investment by these companies. In addition, increasing approvals for new drugs in this region is also expected to drive growth during the forecast period. For instance, in February 2018, Fycompa received FDA approval for treating kidney cancer that has spread to other parts of the body.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising healthcare expenditure and improving economic conditions in emerging countries like China and India which are major markets of this region such as China and India respectively (Global Burden of Disease). Moreover, growing awareness about early diagnosis among people will further boost revenue generation opportunities during future years due to increased demand from clinics along with hospitals across these regions eventually driving regional market share over time.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is one of the key growth drivers for the small molecule inhibitors for cancer therapy market. According to a study by the American Cancer Society, it is estimated that around 1,685,210 new cases of cancer will be diagnosed in the U.S. in 2017 and around 600,920 people will die from this disease. This high incidence rate is expected to drive demand for small molecule inhibitors for cancer therapy over the forecast period.
- Rising prevalence of lifestyle-associated cancers: The rising prevalence of lifestyle-associated cancers such as obesity and smoking is another key factor driving growth in the small molecule inhibitors for cancer therapy market over the forecast period. These types of cancers are more prevalent among developed countries and their incidence rates are expected to rise further in coming years due to changing lifestyles among people across these regions
Scope Of The Report
Report Attributes
Report Details
Report Title
Small Molecule Inhibitors for Cancer Therapy Market Research Report
By Type
Tyrosine Kinase Inhibitor, Histone Deacetylase Inhibitor, Target of Rapamycin Inhibitor
By Application
Hospital, Clinic, Other
By Companies
AstraZeneca, Novartis, Bayer, Roche, Pfizer, Beida Pharma, Bristol-Meyer Squibb, Qilu Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
208
Number of Tables & Figures
146
Customization Available
Yes, the report can be customized as per your need.
Global Small Molecule Inhibitors for Cancer Therapy Market Report Segments:
The global Small Molecule Inhibitors for Cancer Therapy market is segmented on the basis of:
Types
Tyrosine Kinase Inhibitor, Histone Deacetylase Inhibitor, Target of Rapamycin Inhibitor
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AstraZeneca
- Novartis
- Bayer
- Roche
- Pfizer
- Beida Pharma
- Bristol-Meyer Squibb
- Qilu Pharma
Highlights of The Small Molecule Inhibitors for Cancer Therapy Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Tyrosine Kinase Inhibitor
- Histone Deacetylase Inhibitor
- Target of Rapamycin Inhibitor
- By Application:
- Hospital
- Clinic
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Small Molecule Inhibitors for Cancer Therapy Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Small molecule inhibitors are drugs that block the action of specific molecules in the body. These drugs can be used to treat a variety of diseases, including cancer. Small molecule inhibitors can target different proteins or chemicals in the body and stop their harmful effects. This can help to prevent cancer from growing and spreading, and may also help to improve patient symptoms.
Some of the major companies in the small molecule inhibitors for cancer therapy market are AstraZeneca, Novartis, Bayer, Roche, Pfizer, Beida Pharma, Bristol-Meyer Squibb, Qilu Pharma.
The small molecule inhibitors for cancer therapy market is expected to register a CAGR of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Small Molecule Inhibitors for Cancer Therapy Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Small Molecule Inhibitors for Cancer Therapy Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Small Molecule Inhibitors for Cancer Therapy Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Small Molecule Inhibitors for Cancer Therapy Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Small Molecule Inhibitors for Cancer Therapy Market Size & Forecast, 2018-2028
4.5.1 Small Molecule Inhibitors for Cancer Therapy Market Size and Y-o-Y Growth
4.5.2 Small Molecule Inhibitors for Cancer Therapy Market Absolute $ Opportunity
Chapter 5 Global Small Molecule Inhibitors for Cancer Therapy Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Small Molecule Inhibitors for Cancer Therapy Market Size Forecast by Type
5.2.1 Tyrosine Kinase Inhibitor
5.2.2 Histone Deacetylase Inhibitor
5.2.3 Target of Rapamycin Inhibitor
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Small Molecule Inhibitors for Cancer Therapy Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Small Molecule Inhibitors for Cancer Therapy Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Small Molecule Inhibitors for Cancer Therapy Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Small Molecule Inhibitors for Cancer Therapy Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Small Molecule Inhibitors for Cancer Therapy Analysis and Forecast
9.1 Introduction
9.2 North America Small Molecule Inhibitors for Cancer Therapy Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Small Molecule Inhibitors for Cancer Therapy Market Size Forecast by Type
9.6.1 Tyrosine Kinase Inhibitor
9.6.2 Histone Deacetylase Inhibitor
9.6.3 Target of Rapamycin Inhibitor
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Small Molecule Inhibitors for Cancer Therapy Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Small Molecule Inhibitors for Cancer Therapy Analysis and Forecast
10.1 Introduction
10.2 Europe Small Molecule Inhibitors for Cancer Therapy Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Small Molecule Inhibitors for Cancer Therapy Market Size Forecast by Type
10.6.1 Tyrosine Kinase Inhibitor
10.6.2 Histone Deacetylase Inhibitor
10.6.3 Target of Rapamycin Inhibitor
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Small Molecule Inhibitors for Cancer Therapy Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Small Molecule Inhibitors for Cancer Therapy Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Small Molecule Inhibitors for Cancer Therapy Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Small Molecule Inhibitors for Cancer Therapy Market Size Forecast by Type
11.6.1 Tyrosine Kinase Inhibitor
11.6.2 Histone Deacetylase Inhibitor
11.6.3 Target of Rapamycin Inhibitor
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Small Molecule Inhibitors for Cancer Therapy Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Small Molecule Inhibitors for Cancer Therapy Analysis and Forecast
12.1 Introduction
12.2 Latin America Small Molecule Inhibitors for Cancer Therapy Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Small Molecule Inhibitors for Cancer Therapy Market Size Forecast by Type
12.6.1 Tyrosine Kinase Inhibitor
12.6.2 Histone Deacetylase Inhibitor
12.6.3 Target of Rapamycin Inhibitor
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Small Molecule Inhibitors for Cancer Therapy Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Small Molecule Inhibitors for Cancer Therapy Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Small Molecule Inhibitors for Cancer Therapy Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Small Molecule Inhibitors for Cancer Therapy Market Size Forecast by Type
13.6.1 Tyrosine Kinase Inhibitor
13.6.2 Histone Deacetylase Inhibitor
13.6.3 Target of Rapamycin Inhibitor
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Small Molecule Inhibitors for Cancer Therapy Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Small Molecule Inhibitors for Cancer Therapy Market: Competitive Dashboard
14.2 Global Small Molecule Inhibitors for Cancer Therapy Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AstraZeneca
14.3.2 Novartis
14.3.3 Bayer
14.3.4 Roche
14.3.5 Pfizer
14.3.6 Beida Pharma
14.3.7 Bristol-Meyer Squibb
14.3.8 Qilu Pharma
